Phase 1 Study of PTX-100 in Patients With Advanced Malignancies With PTCL Expansion Cohort

Summary

This is an open-label, non-randomized study to evaluate the PD, PK, and safety of 500 to 2000 mg/m2 PTX-100 in patients with advanced malignancies. PTX-100 will be administered by IV infusion over 60 minutes on days 1 to 5 of a 14-day cycle for 4 cycles unless toxicity is observed. Dose escalation is complete and the expansion is open and actively recruiting PTCL patients.

Timeline

Start

2019-09-01

Primary completion

2025-07-31

Completion

2025-08-08

Drugs

Indications